Published in J Clin Endocrinol Metab on March 30, 2012
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int (2015) 0.86
Marrow fat and bone: review of clinical findings. Front Endocrinol (Lausanne) (2015) 0.86
Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Acta Orthop (2015) 0.84
Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol (2014) 0.84
Serum sclerostin levels vary with season. J Clin Endocrinol Metab (2013) 0.83
Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res (2013) 0.83
Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. Arthritis Res Ther (2014) 0.80
Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab (2013) 0.80
The Chinese skeleton: insights into microstructure that help to explain the epidemiology of fracture. Bone Res (2014) 0.80
Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice. J Histochem Cytochem (2015) 0.78
Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab (2014) 0.78
The alliance of mesenchymal stem cells, bone, and diabetes. Int J Endocrinol (2014) 0.78
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul) (2014) 0.77
Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone (2015) 0.77
Has sclerostin a true endocrine metabolic action complementary to osteocalcin in older men? Osteoporos Int (2016) 0.76
Sclerostin serum levels in patients with systemic autoimmune diseases. Bonekey Rep (2016) 0.76
Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Biomed Res Int (2017) 0.75
Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. Curr Osteoporos Rep (2016) 0.75
Serum and tissue biomarkers in aortic stenosis. Glob Cardiol Sci Pract (2015) 0.75
Ischemic heart disease is associated with lower cortical volumetric bone mineral density of distal radius. Osteoporos Int (2015) 0.75
The Utility of Biomarkers in Osteoporosis Management. Mol Diagn Ther (2017) 0.75
Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. Osteoporos Int (2016) 0.75
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J (2005) 3.61
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res (2011) 3.25
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res (2005) 2.61
Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab (2010) 2.05
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab (2010) 1.98
Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem (2004) 1.91
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone (2004) 1.71
The natural history of sclerosteosis. Clin Genet (2003) 1.58
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int (2011) 1.23
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int (2004) 1.07
Nonresponders to osteoporosis therapy. J Clin Densitom (2003) 0.97
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA (2011) 4.83
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 3.50
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med (2005) 3.39
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Duration of lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol (2009) 3.18
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med (2011) 3.17
Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci (2007) 3.16
Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007) 3.15
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc (2009) 3.09
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc (2002) 3.03
Fetuin-A and incident diabetes mellitus in older persons. JAMA (2008) 2.92
The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci (2014) 2.84
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell (2009) 2.79
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78
Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci (2006) 2.73
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med (2008) 2.66
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
Informed Consent. N Engl J Med (2017) 2.56
Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 2.55
Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat (2005) 2.53
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 2.46
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45
Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA (2002) 2.44
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Relationship of changes in physical activity and mortality among older women. JAMA (2003) 2.42